Design, Molecular Docking, and Pharmacokinetic Evaluation of Naproxen-Based 2‑Azetidinone Derivatives for Cancer Treatment

Read full text Summarise with VIRAT
Authors: Noor Riyadh Mahmood, Ayad Kareem Khan, Mohammad M. Al-Akaidi, Mohammed Dheyaa Al-Ameedee
Cited by: 0
References: 24

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study investigates the design, molecular docking, and ADME properties of six novel naproxen derivatives featuring a 2-azetidinone ring, targeting EGFR kinase. Molecular docking was conducted using the crystal structure of the EGFR mutant complexed with Osimertinib (PDB ID: 6LUD). The derivatives were compared with Osimertinib using GOLD software to evaluate binding affinity and fitness. Results showed that several compounds exhibited stronger predicted binding interactions within the EGFR active site, with NR1 and NR2 displaying notably high PLP fitness scores (75.14 and 73.90, respectively). ADME analysis via SwissADME confirmed that all compounds complied with Lipinski’s Rule of Five and exhibited favorable pharmacokinetic properties, including high gastrointestinal absorption and drug-likeness, which supports their potential for oral bioavailability. These computational findings suggest that the derivatives may serve as promising candidates for EGFR inhibition; however, experimental studies are required to validate their biological efficacy and therapeutic potential against mutation-mediated resistance. Overall, the results underscore the potential of 2-azetidinone-based naproxen derivatives as pharmacokinetically viable EGFR inhibitors, warranting further cellular and in vivo evaluation.

Fields of Study & Subjects

Computational Drug Discovery Methods Heterocyclic Compound Synthesis and Bioactivity Synthesis and Characterization of Heterocyclic Compounds

Publication details

Journal / source
Al Mustansiriyah Journal of Pharmaceutical Sciences
Volume
26
Issue
1
Pages
22–37
Publication date
31 March 2026
Language
EN